Urokinase-like plasminogen activator as a marker of endometrial neoplasia

O. Niklasson, L Svanberg, Jan I. Thorell, I. Lecanderb, Birger Åstedt
In: Cancer · 1981 · vol. 48(6) , pp. 1484–1486 · doi:10.1002/1097-0142(19810915)48:6<1484::aid-cncr2820480634>3.0.co;2-l · PMID:7196798 · W2079894469
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Urokinase-like plasminogen activator levels were significantly higher in uterine aspirates from patients with malignant endometrial histology compared to those with normal histology or hyperplasia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Urokinase-like plasminogen activator (ULPA) was determined with a radioimmunoassay in uterine aspirates from 67 patients prior to curettage. In women with normal endometrial histology the mean concentration of ULPA was 5.4 +/- 2.5 microgram per liter. Only one of this aspirates contained more than 8 microgram per liter. In cases with malignant histology ULPA was above this level in 10 of 11 with a mean concentration of 31.2 +/- 31.4 microgram per liter. In cases with glandular cystic hyperplasia and/or adenomatous hyperplasia 6 of 15 had values above 8 microgram per liter with a mean of 10.3 +/- 6.1 microgram per liter. In addition to other parameters of malignancy such as cytology, detection of ULPA in uterine fluid might prove useful in screening examinations for endometrial neoplasia.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (24)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK